Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC. Video Player is loading. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_ERR_SRC_NOT_...
Indications For certain adults with advanced non-small cell lung cancer (NSCLC) OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when ...
After you're diagnosed with non-small-cell lung cancer (NSCLC) that has spread (metastatic), you'll likely get treatments like chemotherapy, radiation, targeted therapy, and immunotherapy. They may help you live longer and lessen symptoms so you feel better. While you're in treatment, there ...
Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) and subsequent development of increasingly effective and central nervous system (CNS)-penetrant first-generation, second-generation and third-generation ALK tyrosine kinase inhibitors (TKIs), the...
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will present with locally advanced disease, requiring multimodality therapy. Des... J Moreira,A Tobias,MP O’Brien,... - 《Drugs》 被引量: 8发表: 2017年 KEYNOTE-224: Phase II study of pembrolizumab in patients with...
Ultimately, the goal of care in younger patients is to prolong life, so aggressive treatment regimens with associated toxicities can be considered to ensure patients obtain the deepest remission possible, Lentzsch says. Although remission is a goal of therapy in older patients, it is equally ...
1 To date, there have been no definite diagnostic methods established for recurrent gastric cancer, and recurrence has mostly been diagnosed using a combinatory analysis of several methods including computed tomography (CT), positron emission tomography (PET), tumor marker evaluation, and even ...
Lung cancer is the third most common cancer in the UK. Around 48,500 people are diagnosed in the UK each year. Of these, around 80 to 85% are NSCLC. Since 2014, TRACERx has been collecting comprehensive genomic and clinical data from people with NSCLC, from their point of diagnosis throu...
The present study showed that a more cost-effective routine follow-up scheme should be advised for patients with completely resected NSCLC, without affecting overall outcome. Routine imaging follow-up is of questionable value, and it may be indicated only in academic settings. 展开 关键词: NSCLC...
Of those who are being offered clinical trials in the community setting, there was a higher likelihood for patients to be offered a clinical trial if their subtype was HER2+ breast cancer subtype or NSCLC with an actionable mutation. Data collection continues as this initiative is ongoing. ...